Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma

Ahmed O Kaseb,1 Yinghui Guan,2,* Betul Gok Yavuz,1,* Alexander R Abbas,2 Shan Lu,2 Elshad Hasanov,3 Han Chong Toh,4 Wendy Verret,5 Yulei Wang2 1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Oncology Biomar...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kaseb AO, Guan Y, Gok Yavuz B, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Dove Medical Press 2022-10-01
Edice:	Journal of Hepatocellular Carcinoma
Témata:	igf-ctp score prognostic biomarker immunotherapy hcc
On-line přístup:	https://www.dovepress.com/serum-igf-1-scores-and-clinical-outcomes-in-the-phase-iii-imbrave150-s-peer-reviewed-fulltext-article-JHC
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!